CG
MCRB icon

Cutler Group’s Seres Therapeutics MCRB Stock Holding History

Cutler Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125
Closed -$2K – 4112
2023
Q2 		$2K Buy
+125
New +$13.6K ﹤0.01% 3053
2021
Q2 		– Sell
-120
Closed -$1K – 6079
2021
Q1 		$1K Sell
120
-25
-17% -$11.5K ﹤0.01% 5279
2020
Q4 		$15K Sell
145
-300
-67% -$176K ﹤0.01% 2904
2020
Q3 		$28K Buy
+445
New +$148K ﹤0.01% 2204
2017
Q4 		– Sell
-60
Closed -$2K – 5492
2017
Q3 		$2K Buy
+60
New +$16.4K ﹤0.01% 5112
2017
Q2 		– Sell
-520
Closed -$3K – 6761
2017
Q1 		$3K Buy
+520
New +$106K ﹤0.01% 5159
2016
Q4 		– Sell
-1,400
Closed -$9K – 6984
2016
Q3 		$9K Buy
1,400
+825
+143% +$289K ﹤0.01% 4326
2016
Q2 		$50K Buy
575
+220
+62% +$129K ﹤0.01% 2352
2016
Q1 		$1K Sell
355
-920
-72% -$480K ﹤0.01% 6037
2015
Q4 		$65K Buy
+1,275
New +$838K ﹤0.01% 2196

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's MCRB Position: Q4 2023 in Review

Cutler Group sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 311 shares — an estimated $14K sold.

Cutler Group first reported a position in MCRB in Q1 2016 and held it in 30 quarters. The position peaked at $186K in Q3 2020. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Cutler Group reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 311 Seres Therapeutics shares in Q4 2023, an estimated $14K.
  • Cutler Group first reported a position in Seres Therapeutics in Q1 2016 and held it in 30 quarters.
  • Cutler Group's Seres Therapeutics position peaked at $186K in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.